Business
Equillium to Present at the SVB Leerink Virtual Global Healthcare Conference
LA JOLLA, Calif.--(BUSINESS WIRE)-- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and
About this update from Equillium, Inc.
[{"type":"text","content":" LA JOLLA, Calif.--(BUSINESS WIRE)--\nEquillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that it will participate in a fireside chat presentation at the SVB Leerink Virtual Global Healthcare Conference, taking place February 14 – 18, 2022.\n\nBruce Steel, Equillium’s chief executive officer, and Steve Connelly Ph.D., Equillium’s chief scientific officer, will provide a high-level overview of the company and ongoing clinical programs. Mr. Steel, Dr. Connelly and other members of Equillium’s leadership team will be available for one-on-one meetings during the conference.\n\n\n\nDate:\n\n\n\n \n\n\n\nWednesday, February 16, 2022\n\n\n\n\n\nTime:\n\n\n\n \n\n\n\n2:20 PM Eastern Time | 11:20 AM Pacific Time\n\n\n\n\n\nLocation:\n\n\n\n \n\n\n\nVirtual Webcast\n\n\n\n\nA live webcast of the presentation will be available under the “Investors” section of the Company’s website at https://ir.equilliumbio.com/events-and-presentations. An archived replay will be available for 90 days.\n\nAbout Equillium\n\nEquillium is a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders with high unmet medical need. Equillium is developing itolizumab for multiple severe immuno-inflammatory diseases, including acute graft-versus-host-disease (aGVHD) and lupus/lupus nephritis.\n\nFor more information, visit www.equilliumbio.com.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20220209005390/en/\n\nInvestor Contact\nMichael Moore\nVice President, Investor Relations & Corporate Communications\n619-302-4431\[email protected]\n\nMedia Contacts\nAljanae Reynolds\nWheelhouse Life Science Advisors\[email protected]\n\nSource: Equillium, Inc.","length":5936,"tagName":"div"}]